Less Ads, More Data, More Tools Register for FREE

LONDON BROKER RATINGS: Deutsche cuts Abrdn; UBS raises Dunelm

Thu, 16th Dec 2021 09:39

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

----------

FTSE 100

----------

UBS STARTS KINGFISHER WITH 'NEUTRAL' - PRICE TARGET 338 PENCE

----------

JEFFERIES RAISES TESCO PRICE TARGET TO 350 (330) PENCE - 'BUY'

----------

MORGAN STANLEY CUTS ANGLO AMERICAN PRICE TARGET TO 2,870 (3,070) PENCE - 'EQUAL-WEIGHT'

----------

BARCLAYS CUTS ANTOFAGASTA PRICE TARGET TO 1,050 (1,100) PENCE - 'UNDERWEIGHT'

----------

MORGAN STANLEY RAISES ASTRAZENECA PRICE TARGET TO 10,200 (10,000) PENCE - 'OVERWEIGHT'

----------

RBC RAISES COMPASS PRICE TARGET TO 1,340 (1,225) PENCE - 'UNDERPERFORM'

----------

CREDIT SUISSE RAISES INFORMA PRICE TARGET TO 673 (635) PENCE - 'OUTPERFORM'

----------

RBC RAISES DCC PRICE TARGET TO 7,500 (7,400) PENCE - 'OUTPERFORM'

----------

DEUTSCHE BANK CUTS ABRDN TO 'HOLD' (BUY) - PRICE TARGET 275 (320) PENCE

----------

FTSE 250

----------

UBS RAISES DUNELM GROUP TO 'BUY' (NEUTRAL) - PRICE TARGET 1,750 (1,300) PENCE

----------

UBS RAISES HOWDEN JOINERY GROUP PRICE TARGET TO 1000 (960) PENCE - 'BUY'

----------

OTHER MAIN MARKET AND AIM

----------

UBS CUTS DFS FURNITURE PRICE TARGET TO 241 (250) PENCE - 'NEUTRAL'

----------

LIBERUM CUTS ON THE BEACH GROUP PRICE TARGET TO 250 (380) PENCE - 'HOLD'

----------

BARCLAYS INITIATES POD POINT WITH 'EQUAL WEIGHT' - TARGET 250 PENCE

----------

CREDIT SUISSE STARTS ITM POWER WITH 'UNDERPERFORM' - PRICE TARGET 340 PENCE

----------

CREDIT SUISSE STARTS CERES POWER WITH 'OUTPERFORM' - PRICE TARGET 1,450 PENCE

----------

JPMORGAN CUTS ALPHAWAVE IP PRICE TARGET TO 311 (450) PENCE - 'OVERWEIGHT'

----------

JEFFERIES INITIATES DIGITAL 9 INFRASTRUCTURE WITH 'HOLD'

----------

JEFFERIES INITIATES CORDIANT DIGITAL INFRASTRUCTURE WITH 'HOLD'

----------

BERENBERG CUTS PETRA DIAMONDS PRICE TARGET TO 83 (96) PENCE - 'HOLD'

----------

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with infla...

18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with pacl...

17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "impo...

17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Ba...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.